T 1639/21 (mRNA/anti-PD-1 combination vaccine/CUREVAC) of 13.03.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T163921.20240313
- Date of decision
- 13 March 2024
- Case number
- T 1639/21
- Petition for review of
- -
- Application number
- 14706481.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Combination of vaccination and inhibition of the PD-1 pathway
- Applicant name
- CureVac SE
- Opponent name
- Schnappauf, Georg
ModernaTX, Inc.
Strawman Limited
eTheRNA Immunotherapies NV
Merck Sharp & Dohme LLC - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112(1)(a)European Patent Convention Art 56
- Keywords
- Inventive step - (no)
Referral to the Enlarged Board of Appeal - (no) - Catchword
- Obviousness of synergistic effect (see points 15 to 18 and 62 to 69)
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.